{{Rsnum
|rsid=166050
|Gene=SRD5A1
|Chromosome=5
|position=6643734
|Orientation=plus
|GMAF=0.1368
|Gene_s=SRD5A1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 61.9 | 31.9 | 6.2
| HCB | 78.8 | 21.2 | 0.0
| JPT | 83.2 | 15.9 | 0.9
| YRI | 100.0 | 0.0 | 0.0
| ASW | 87.7 | 10.5 | 1.8
| CHB | 78.8 | 21.2 | 0.0
| CHD | 72.5 | 25.7 | 1.8
| GIH | 73.3 | 20.8 | 5.9
| LWK | 97.2 | 2.8 | 0.0
| MEX | 67.2 | 29.3 | 3.4
| MKK | 83.3 | 15.4 | 1.3
| TSI | 55.9 | 36.3 | 7.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=23499746
|Title=SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}